共 277 条
[1]
Schneeweiss A(2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 2278-2284
[2]
Chia S(2016)Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis JAMA Oncol 2 751-760
[3]
Hickish T(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
[4]
Harvey V(2011)Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Breast Cancer Res Treat 125 145-156
[5]
Eniu A(2016)Highlights from the Tenth European Breast Cancer Conference (EBCC10), Amsterdam, 9–11 March 2016 Ecancermedicalscience 10 644-26
[6]
Hegg R(2008)MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 17-167
[7]
Tausch C(2014)Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology J Surg Oncol 109 158-1638
[8]
Seo JH(2014)Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment Eur J Radiol 83 1631-795
[9]
Tsai YF(2016)Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol 23 789-79
[10]
Ratnayake J(2016)Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype SpringerPlus 5 152-333